R
Ryder System, Inc.·Industrials
244.00
2.328%(+5.55)
Market ClosedLast Updated: — ET
52W L: $143.3452W H: $259.00
R NEWS
accessnewswire.com
1d ago
BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO
BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination synergy with pembrolizumab Cohort expansion is underway, focusing on high-grade serous and clear cell subtypes, with another data readout expected in H2 2026 LUND, SE / ACCESS Newswire / May 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer.
newsfilecorp.com
3d ago
Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering") of 19,166,667 units ("Units") of the Company at a price of C$0.24 per Unit ("Offering Price") for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").
newsfilecorp.com
4d ago
Vera Quinn of Cydcor Named Entrepreneur Of the Year(R) 2026 Greater Los Angeles Finalist by EY US
EY US celebrates ambitious entrepreneurs shaping the future of business Los Angeles, California--(Newsfile Corp. - May 19, 2026) - Vera Quinn, CEO of Cydcor, has been named a finalist for the Entrepreneur Of The Year 2026 Greater Los Angeles Award by Ernst & Young LLP (EY US). Now in its 41st year, the Entrepreneur Of The Year program celebrates the bold leaders who disrupt markets through the world's most ground-breaking companies, revolutionizing industries and uplifting communities.
newsfilecorp.com
4d ago
GMG's THERMAL-XR(R) to be Applied Exclusively & Distributed to Global Oil and Gas/LNG Industry with Curran International
Brisbane, Queensland, Australia--(Newsfile Corp. - May 19, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the signing of a global distribution agreement with Curran International for THERMAL-XR® and for exclusive application services for the product oil and gas/LNG industry. Curran International is a global leader in providing heat transfer technologies to some of the world's largest oil and gas companies.
accessnewswire.com
5d ago
Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference
LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor uptake of ¹⁷⁷Lu-SN201 in two individuals with different head and neck cancers.
zacks.com
May 14
Are Investors Undervaluing Ryder System (R) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
